摘要磺脲类药物是经典的促胰岛素分泌剂,而二肽基肽酶(DPP)-Ⅳ抑制剂为2型糖尿病患者提供了新的选择.磺脲类药物疗效好,能预防微血管并发症,但因其非葡萄糖依赖性的降糖方式易引发低血糖,且临床试验证实易增加体重,由于损耗β细胞功能存在继发失效,并不是最为理想的选择.DPP-Ⅳ抑制剂降糖效果不劣于磺脲类,低血糖发生率低,可减轻或不影响体重,保护胰岛细胞功能,但尚缺乏关于长期疗效及安全性的5年以上的研究.如何合理选用降糖药物应根据临床情况综合评估.

abstractsSulfonylureas (SUs) are classic insulin-secretagogues while dipeptidyl peptidase-Ⅳ (DPP-Ⅳ) inhibitors have emerged as new alternatives for patients with type 2 diabetes.SUs show good anti-diabetic efficacy and have been shown to prevent microvascular complications,however,it is also associated with a high frequency of hypoglycemia because of glucose-independent manner.Meanwhile,increased body weight,and a high risk of secondary failure make SUs a less desirable choice.DPP-Ⅳ inhibitors present simi-lar efficacy as SUs but lower risk of hypoglycemia,and reduction or no change in body weight,also preserva-tion of islet function.However,long-term experience (＞ 5 years) on efficacy and safety is still lacking.Prop-er selection of the oral anti-diabetic drugs depends on an overall evaluation of clinical situation.